npj Genomic MedicineGeneticsPeer-reviewed journal article
ATP7B Variant c.1934T>G p.Met645Arg Causes Wilson Disease by Promoting Exon 6 Skipping
Daniele MericoiD, Carl SpickettiD, Matthew O’Hara, Boyko KakaradoviD, Amit G. DeshwariD, Phil Fradkin, Shreshth GandhiiD, Jiexin Gao, Solomon Grant, Ken J. KroniD, Frank W. Schmitges, Zvi ShaleviD, Mark Sun, Marta Verby, Matthew Cahill, James J. DowlingiD, Johan FranssoniD, Erno Wienholds, Brendan J. Frey
- Citations
- 23
- FWCI
- 1.03
- Field percentile
- top 27%
Abstract
Wilson Disease is a recessive genetic disorder caused by pathogenic loss-of-function variants in the ATP7B gene. It is characterized by disrupted copper homeostasis resulting in liver disease and/or neurological abnormalities. The variant NM_000053.3:c.1934T>G (Met645Arg) has been reported as compound heterozygous and is highly prevalent among Wilson Disease patients of Spanish descent. Accordingly, it is classified as pathogenic by leading molecular diagnostic centers. However, functional studies suggest that the amino acid change does not alter protein function, leading one ClinVar submitter to question its pathogenicity. Here we used a minigene system and gene-edited HepG2 cells to demonstrate that c.1934T>G causes approximately 70% skipping of exon 6. Exon 6 skipping results in frameshift and stop gain, which is expected to cause loss of ATP7B function. The elucidation of the mechanistic effect for this variant resolves any doubt about its pathogenicity and enables the development of genetic medicines for restoring correct splicing.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A study of Mutation in ATP7B gene and its correlation with clinical phenotype and radiological features in Wilson Disease patients
Jasodhara Chaudhuri, Samar Biswas, … Avijit Hazra·bioRxiv·Jan 21, 2021
- ATP7B variant penetrance explains differences between genetic and clinical prevalence estimates for Wilson disease
Daniel F. Wallace, James S. Dooley·Human GeneticsPeer-reviewed·Apr 4, 2020
- Benchmarking Computational Methods for Estimating the Pathogenicity of Wilson’s Disease Mutations
N. Tang, T. Sandahl, … K. P. Kepp·bioRxiv·Sep 25, 2019
- A Dual-Function Guanidinium Scaffold that Couples Copper Sequestration with Redox Protection in Wilson disease
Raviranjan Pandey, Arpan Narayan Roy, … Arnab Gupta·bioRxiv·Jun 15, 2026
- Repurposing Melatonin in dual-mode for Wilson disease therapy as a Copper Chelator and an antioxidant agent
Raviranjan Pandey, Arpan Narayan Roy, … Arnab Gupta·bioRxiv·Aug 30, 2025
- The role of intestine in metabolic dysregulation in murine Wilson disease
Gaurav V. Sarode, Tagreed A. Mazi, … Valentina Medici·Hepatology CommunicationsPeer-reviewed·Sep 11, 2023